Home > Insider Trading > Filing (0000899243-17-025425)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1624658	Allena Pharmaceuticals Inc.	ALNA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1180428	J Mark Levin	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1192603	P Kevin Starr	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1488495	Third Rock Ventures Ii, L.p.	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1614061	Third Rock Ventures Gp Ii, L.p.	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1614073	Trv Gp Ii, Llc	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-06	2,575,964	$0.00	2,575,964	No	4	C	Direct
Common Stock	Acquisiton	2017-11-06	215,000	$14.00	2,790,964	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2017-11-06	6,122,448	$0.00	1,466,805	$0.00
Common Stock	Series B Preferred Stock	Disposition	2017-11-06	4,629,630	$0.00	1,109,159	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Represents the total number of shares of Common Stock received by Third Rock Ventures II, L.P. ("TRV II") upon conversion of the Series A Preferred Stock and Series B Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.
The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
Represents shares of Common Stock purchased by TRV II in the Issuer's initial public offering.